Century Therapeutics Joins Forces with Experts for Groundbreaking Autoimmune Therapy Trial

Century Therapeutics, Inc. (NASDAQ: IPSC), a leader in biotechnology, is collaborating with Professors Georg Schett and Andreas Mackensen for a pivotal investigator-initiated trial of its CNTY-101 therapy. Known as the CARAMEL trial, this Phase 1/2 study marks the first use of allogeneic iPSC-derived CD19 CAR-iNK cells to tackle autoimmune conditions like systemic lupus erythematosus, lupus nephritis, and diffuse cutaneous systemic sclerosis. Backed by Friedrich-Alexander University Erlangen-Nürnberg, the trial builds on the promising safety and efficacy data of Century’s CALiPSO-1 trial.

Brent Pfeiffenberger, CEO of Century Therapeutics, hailed the collaboration as a major milestone, highlighting the potential of CNTY-101 to redefine autoimmune care with its innovative Allo-Evasion™ technology. Dr. Andreas Mackensen emphasized the trial's promise to simplify treatment with its off-the-shelf product, eliminating logistical barriers like apheresis. Set to launch in mid-2025, the CARAMEL trial is poised to complement Century’s global efforts to deliver transformative outcomes for patients with unmet medical needs.